Macquarie Group’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

Macquarie Group’s Portfolio EBACU Stock Details EBACU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-378,000	Closed	-$3.78M	–	2672
2021 Q2	$3.78M	Hold	378,000	–	–	﹤0.01%	1219
2021 Q1	$3.81M	Buy	+378,000	New	+$3.78M	0.01%	989

Other funds holding EBACU

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

SMA

Sage Mountain Advisors Atlanta, Georgia $1.63B AUM 18.97% 1-Year Est. Return

Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return

MTCM

Mint Tower Capital Management Amsterdam, Netherlands $871M AUM 8.61% 1-Year Est. Return

Macquarie Group's EBACU Position: Q3 2021 in Review

Macquarie Group sold out of European Biotech Acquisition Corp. Units (EBACU) in Q3 2021, closing a stake of 378,000 shares — an estimated $3.78M sold.

Macquarie Group first reported a position in EBACU in Q1 2021 and held it in 2 quarters. The position peaked at $3.81M in Q1 2021. 30 funds tracked by Wall St. Rank hold EBACU as of Q3 2021.

Macquarie Group reported no remaining European Biotech Acquisition Corp. Units position as of Q3 2021 after selling out during the quarter.
Macquarie Group sold 378,000 European Biotech Acquisition Corp. Units shares in Q3 2021, an estimated $3.78M.
Macquarie Group first reported a position in European Biotech Acquisition Corp. Units in Q1 2021 and held it in 2 quarters.
Macquarie Group's European Biotech Acquisition Corp. Units position peaked at $3.81M in Q1 2021.
30 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q3 2021.

Based on Macquarie Group's 13F filing for Q3 2021, filed 12 Nov 2021.